VIVEbiotech brings in industry veteran Patricio Massera as president to steer global expansion

Spanish gene therapy specialist VIVEbiotech has named Patricio Massera as its new president, bringing in a seasoned CDMO leader to help scale the business following a fresh investment from US firm Ampersand Capital Partners.

The appointment signals a major step in the company’s push to expand internationally and strengthen its position in lentiviral vector development and manufacturing. Mr Massera, who will also continue as a board member, is expected to drive growth and operational improvements.

He joins after more than two decades in the contract manufacturing space, most recently as chief executive of AGC Biologics, where he oversaw global expansion and worked to improve service quality and innovation.